Physician profile
John D Crase
NPI 1902820798
$3,533.34
in general payments reported to CMS, 2019-2025
31 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $982 · 2021: $601 · 2022: $13.71 · 2023: $207 · 2024: $292 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $772.96 | 2019-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $465.08 | 2020-2021 | |
| Glaxosmithkline, LLC. | $343.10 | 2019-2024 | Shingrix, Arexvy |
| Allergan, INC. | $333.96 | 2019-2020 | |
| Exact Sciences Corporation | $310.33 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $143.01 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $142.01 | 2024-2025 | Voquezna |
| Pfizer INC. | $140.18 | 2019-2021 | |
| Lilly USA, LLC | $125.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.39 | 2019-2021 | |
| Eisai INC. | $75.41 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $70.23 | 2019-2020 | |
| Astellas Pharma US INC | $66.74 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $61.90 | 2019 | |
| Novo Nordisk INC | $50.78 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.98 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.84 | 2019 | |
| Esperion Therapeutics, INC. | $31.36 | 2020-2021 | |
| Circassia INC. | $30.14 | 2019 | |
| Amarin Pharma, INC. | $28.97 | 2019 | |
| Philips North America LLC | $26.55 | 2025 | Holter |
| Amgen INC. | $24.09 | 2019 | |
| Sanofi Pasteur INC. | $19.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2020 | |
| Abbvie INC. | $13.12 | 2024 | |
| Daiichi Sankyo INC. | $13.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.